Merck To File Two More Gardasil sBLAs In Late 2007/Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck seeks more indications for HPV vaccine in women ages 27 to 45 and men 16 to 26, but expects less rapid sales growth than in original approval group.
You may also be interested in...
Merck Gardasil sBLA Gets Priority Review In Older Women
Company seeks approval of the vaccine for women ages 27 through 45.
Merck Gardasil sBLA Gets Priority Review In Older Women
Company seeks approval of the vaccine for women ages 27 through 45.
GSK Cervarix Setback: FDA Questions On HPV Vaccine Bode Well For Merck
The launch of GlaxoSmithKline human papilloma virus vaccine Cervarix will be further delayed behind Merck's competing Gardasil vaccine after FDA issued a "complete response" letter related to the BLA Dec. 17